Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Treatment of patients with perioxisome proliferator-activated receptor-¿ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator-activated receptor-¿ agonists has not been established in a clinical trial. The BALaglitazone glucose Lowering Efficacy Trial aimed to establish the glucose-lowering effects and safety parameters of the perioxisome proliferator-activated receptor-¿ partial agonist balaglitazone in diabetic patients on stable insulin therapy.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Diabetes - Metabolism: Research and Reviews (Print Edition) |
Vol/bind | 27 |
Udgave nummer | 4 |
Sider (fra-til) | 392-401 |
Antal sider | 10 |
ISSN | 1520-7552 |
DOI | |
Status | Udgivet - 2011 |
ID: 40188970